Summary
The long-term effects of high dose steroid treatment with either prednisone (PDN) or deflazacort (DFZ) were examined on various parts of the skeleton in 29 patients with nephrotic syndrome. All had normal skeleton at the start of the steroid treatment. At the beginning, PDN was given as 80 mg/day and tapered down to 20 mg/day for 1 year and DFZ was given in an equipotent dosage. Twenty-three patients completed 6 months of treatment, and 18 patients completed 12 months of treatment. Beside laboratory parameters to ensure the effect of treatment on the nephrotic syndrome, all had measurements of the bone mineral content (BMC) at 0, 6, and 12 months of treatment. BMC was measured by single photon absorptiometry of both forearms and by dual photon absorptiometry of the mandible, forearms, and lumbar spine. The effect of DFZ was compared to that of PDN due to a potential “calcium sparing” effect of DFZ. The therapeutical effects on the nephrotic syndrome were not different between the two drugs. Urinary 24-hour protein decreased from 9.9 to 1.1 g in the DFZ-treated patients and from 8.0 to 1.4 g in the PDN-treated patients. Plasma albumin concentration normalized in both groups. Both groups of steroid-treated patients had a significant reduction of the BMC levels in all parts of the skeleton. However, the bone decay rates per month were significantly different between different bone regions and between different drug regimes. In the forearm, the bone decay rate was 5.3%/year in the PDN group and 2.0%/year in the DFZ group (P<0.001). In the mandible, decay rate was 7.0%/year in both groups, and in the lumbar spine it was 12.5%/year in the PDN group and 6.8%/year in the DFZ group (P<0.01). Thus, the bone loss in the PDN-treated group was significantly higher than that of the DFZ-treated patients, despite a similar therapeutical effect on the nephrotic syndrome. Therefore, the detrimental effect of long-term steroid treatment on the skeleton may not be abolished, but can be reduced significantly by using deflazacort instead of prednisone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Raisz LG (1989) Steroids and osteoporosis an unsolvable problem? In: Kleerekope M, Krane SM (eds). Clinical disorders of bone and mineral metabolism. Mary Ann Liebert pp 211–217
Reid IR (1989) Steroid osteoporosis. Calcif Tissue Int 45:63–67
Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BEC (1990) Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46:305–308
Hahn TJ, Halstead LR, Strates B, Imbimbo B, Baran DT (1980) Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man. Calcif Tissue Int 31:109–115
Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1:37–192
Krolner B, Nielsen SP (1980) Measurement of bone mineral content (BMC) of the lumbar spine. I. Theory and application of a new two-dimensional dual-photon attenuation method. Scand J Clin Lab Invest 40:653–663
Wowern Nina v, Storm TL, Olgaard K (1988) Bone mineral content by photon absorptiometry of the mandible compared with that of the forearm and the lumbar spine. Calcif Tissue Int 42:157–161
Christiansen C, Rodbro P, Jensen H (1975) Bone mineral content in the forearm measured by photon absorptiometry. J Clin Lab Invest 35:323–330
Sorensen OH, Storm TL, Thamsborg G, Lund B, Lind L, Ljunghall S (1986) Vitamin D metabolism and osteodensitometry in diabetes. In: Serrano-Rios M, LeFebre PJ (eds) Proc 12th Cong Intl Diabetes Fed. Excerpta Medica, Amsterdam, New York, Oxford, 754–758
Daugaard H, Egfjord M, Olgaard K (1988) Metabolism of intact parathyroid hormone in isolated perfused rat liver and kidney. Am J Physiol 254:E740–748
Reinhardt TA, Horst RL, Orf JW, Hollis BW (1984) A microassay for 1,25-dihydroxyvitamin D not requiring high-performance liquid chromatography: application to clinical studies. J Clin Endocrinol Metab 58:91–98
Armitage P, Berry DA (1987) Statistical methods in medical research. Blackwell, Oxford, 222–226
SAS Institute Inc (1985) SAS introductory guide for personal computers, version 6 edition, Cary, NC
Draper NR, Smith H (1981) Applied regression analysis, John Wiley, New York, pp 218–279
Searle SR (1971) Linear models. John Wiley, New York
Dempster DW, Arlott MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410–417
Greenberger PA, Hendrix RW, Patterson R, Chmiel JS (1982) Bone studies in patients on prolonged systemic corticosteroid therapy for asthma. Clin Allergy 12:363–368
Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G (1986) Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. Br Med J 293:1463–1466
Sambrook P, Birmingham J, Kempler S, Kelly P, Eberl S, Pocock N, Yeates M, Eisman J (1980) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211–1216
Adinoff AD, Hollister JR (1983) Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265–268
Ruegsegger P, Medici TC, Anliker M (1983) Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 25:615–620
Imbimbo B, Tuzi T, Porzio F, Schiavetti L (1984) Clinical equivalence of a new glucocorticoid, deflazacort, and prednisone in rheumatoid arthritis and S.L.E. patients. Adv Exp Med Biol 171:241–256
Balsan S, Stern D, Bourdeau A, Grimberg R, Lenoir G (1987) Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth. Calcif Tissue Int 40:303–309
Sutton RAL, Dirks JH (1986) Calcium and magnesium, renal handling and disorders of metabolism. In: Brenner BM, Kector FC Jr (eds) The kidney. WB Saunders, Philadelphia, pp 563–564
Aubia J, Masramón J, Serrano S, Marinoso LI, Bosch J, Lloveras J (1990) Cyclosporine delays healing of osteodystrophy in renal transplanted patients. Kidney Int 37:1603
McCauley LK, Rosol TJ, Capen CC (1989) Effects of interleukin-1 and cyclosporine A on serum calcium and bone resorption in vivo and in vitro (abstract 781) J Bone Miner Res 4 (suppl 1):S288
Assandri A, Buniva G, Martinellei E, Perazzi A, Zerilli L (1984) Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man. In: Avioli LV, Gennari C, Imbimbo B (eds) Glucocorticoid effects and their biological consequences. Plenum Publishing, pp 9–23
Martinelli E, Ferrari P, Ripamonti A, Tuan G, Perazzi A, Assandri A (1979) Metabolism of deflazacort in the rat, dog and man. Drug Metab Dispos 7:335–339
Assandri A, Perazzi A, Buniva G, Pagani V (1980) Disposition of a new steroidal anti-inflammatory agent, deflazacort, in rat, dog and man. Eur J Drug Metab Pharmacokin 207–215
Langhoff E, Olgaard K (1986) In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol 21:125–129
Oriente P, Pucino A, Scarpa R, Vignone L (1986) Deflazacort vs. prednisone during the prolonged treatment of systemic connective diseases in the acute flare-up stage: assessment of the potency ratio. In: Avioli VL, Gennari C, Imbimbo B (eds) Glucocorticoid effects and their biological consequences: advances in glucocorticoid therapy. Excerpta Medica, Amsterdam, pp 61–70
Gennari C, Imbimbo B (1985) Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 37:592–593
Nagant De Deuxchaisnes C, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Stasse P, Canh Le Thi T (1986) The effects of small doses of deflazacort vs. prednisone on the bone mineral content of the lumbar spine in male patients with rheumatoid arthritis. In: Avioli VL, Gennari C, Imbimbo B (eds) Glucocorticoid effects and their biological consequences: advances in glucocorticoid therapy. Excerpta Medica, Amsterdam, pp 145–151
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olgaard, K., Storm, T., Wowern, N.V. et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 50, 490–497 (1992). https://doi.org/10.1007/BF00582160
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00582160